Two Beta-Blockers, One Closing Time
Thursday, 5:40 p.m. A 62-year-old woman hands over a new e-prescription from a walk-in clinic: metoprolol succinate ER 25 mg, take 1 tablet by mouth twice daily, quantity 60, no refills. She also sets down a bottle your pharmacy filled 3 weeks ago: metoprolol tartrate 25 mg, 1 tablet twice daily, with 2 refills remaining. She says the clinic doctor told her the long-acting one works better. Her cardiologist is out of the office until Monday; the walk-in clinic closes at 6:00 p.m. The claim rejects on a therapeutic-duplication DUR alert and a formulary message: succinate ER requires prior authorization, tartrate is preferred. She has 3 tablets left, her blood pressure today is 148/88 with a heart rate of 76, and she asks whether she can just pay cash to skip the hassle.
1. The dosing directions and the duplicate therapy both need to be resolved before anything leaves the counter. What do you verify, and can you dispense tonight?
Read the worked answer
What is actually wrong
- Metoprolol succinate ER is a once-daily product. "Twice daily" is not a labeled regimen and is the classic fingerprint of an order where the prescriber meant either succinate 50 mg once daily or tartrate 25 mg twice daily. Do not silently interpret it either way.
- She has an active tartrate prescription with refills left, so the DUR duplication alert is a true positive, not noise. Filling both means two beta-blockers in the same body.
- Succinate ER and tartrate are not interchangeable under generic substitution. Switching products is a prescriber decision, not a pharmacist convenience.
What you verify before dispensing
- Call the clinic now, before 6:00, with a closed question: "Was the intent succinate 50 mg once daily, or to continue tartrate 25 mg twice daily?" Ask them to send a corrected order either way.
- If the answer is "switch to ER," ask them to discontinue the tartrate so the profile and the refill history are clean.
- Confirm the prescriber's identity and that this clinic has a working callback number.
Can you dispense tonight? Not as written. Resolve the frequency and the duplication first. She is not in acute danger: 3 tablets left covers 1.5 days, BP 148/88 with HR 76 is not urgent, and a delay of one business day is clinically acceptable. Do not create a bridge supply of a new product on your own authority. If state law permits an emergency refill for maintenance medication, that provision could cover continuing the tartrate if you cannot reach anyone - but only the same drug she is already on, never a product switch.
2. The claim rejects. Walk through what you do about the DUR override and the prior authorization, and what you tell her about paying cash.
Read the worked answer
The DUR alert Therapeutic-duplication overrides exist for alerts that are not clinically real (for example, a patient on both an aspirin product and a combination product containing aspirin). Here the duplication is real, so an override with a false rationale is not a legitimate workaround. The correct fix is a discontinued tartrate order on the profile, not a click-through.
The prior authorization
- The formulary message and the PA are separate from the clinical question. Tell the prescriber's office now that the PA exists so they can start it; do not wait for it to resolve the dosing error.
- If the corrected order is succinate ER, expect the PA to be the next obstacle. Ask the clinic what documentation the plan wants and offer to send the fill history showing the tartrate trial.
- Do not dispense on a PA-pending claim and hope it pays.
Paying cash
- Yes, a patient may choose to pay cash. Give her the real self-pay price for the ER product, not a vague estimate, and compare it to what the tartrate currently costs her.
- Explain the trade-off plainly: a cash fill is not billed to the plan, so it will not count toward her deductible or out-of-pocket maximum, and she cannot later submit the same fill to the plan for reimbursement.
- Do not bill the plan and also collect a cash equivalent for the same dispense. That is a billing integrity issue, and it is the kind of thing that shows up in an audit.
3. It is 5:55 p.m. and the clinic line is busy. What is your documentation and follow-up plan for tonight?
Read the worked answer
Documentation
- Time-stamped record of every call attempt, which number, who answered, and what exactly was asked.
- The specific unresolved question in writing: is the intent succinate 50 mg once daily, or continuation of tartrate 25 mg twice daily?
- What the patient was told, by whom, and when she should expect to hear back.
- A hard flag on both prescriptions in the system so the next pharmacist does not fill on autopilot while the question is open.
What she needs tonight
- Keep taking the tartrate exactly as before; do not add, double, or skip a dose.
- Call the clinic or her cardiologist Monday morning and ask for a corrected prescription.
- Call the pharmacy or seek care for a heart rate under about 50, unusual dizziness, fainting, or worsening shortness of breath.
- Give her a realistic callback: "I will call you by 10 a.m. tomorrow with what the prescriber said."
Follow-up ownership Assign it to a named person and a shift, not "whoever is here." A note on the bag or the bin is not a handoff system. Also send a portal message or fax tonight so the clinic sees the question first thing, and note that you did.
Why the delay is defensible The patient is hemodynamically stable, has 1.5 days of drug remaining, and the open question is a dosing-frequency error plus a duplicate therapy. A one-business-day delay to prevent double-dosing a beta-blocker is the safer error.